Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation
Open Access
- 12 June 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Abstract
Background: Peripheral neuropathy frequently leads to linezolid dose reductions or interruptions during multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. The implications of these modifications on treatment success are uncertain. Methods: We conducted a target trial emulation using the endTB Observational Study among individuals who developed non-severe peripheral neuropathy while receiving linezolid 600 mg daily within 6 months of initiating an individualized MDR/RR-TB regimen. We examined three linezolid management strategies: immediate change (i.e., dose reduction, temporary interruption, discontinuation) within Weeks 1–7 after peripheral neuropathy onset, deferred change within Weeks 8–26, and no change (i.e., continuing linezolid 600 mg daily) during Weeks 1–26. To emulate the per-protocol analysis of a trial, we used an approach involving cloning and censoring participant data, and applying inverse probability of censoring weights. Results: Among 303 eligible participants from 12 countries, peripheral neuropathy occurred a median of 11 weeks (interquartile range: 4–18) after treatment initiation. Weighted, standardized probabilities of treatment success were 84.7% (95% CI: 69.2%, 92.9%) for immediate change, 78.9% (95% CI: 65.9%, 87.1%) for deferred change, and 85.2% (95% CI: 80.5%, 89.1%) for no change. Compared with no change, treatment success ratios were 0.99 (95% CI: 0.83, 1.11) for immediate change and 0.93 (95% CI: 0.78, 1.01) for deferred change. Conclusions: We did not find evidence of a substantial negative impact of immediate modification to linezolid on MDR/RR-TB treatment success. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.Keywords
Funding Information
- Unitaid
- National Institutes of Health (R01AI146095)
This publication has 37 references indexed in Scilit:
- Treatment outcomes and drug-related adverse events across four short-course RR-TB regimens in South Africa: A retrospective analysisInternational Journal of Infectious Diseases, 2026
- Peripheral NeuropathyJAMA, 2026
- Long term outcomes in drug resistant tuberculosis with Bedaquiline, Pretomanid and varying doses of LinezolidJournal of Infection, 2025
- Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosisInternational Journal of Antimicrobial Agents, 2024
- Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter studyIndian Journal of Tuberculosis, 2023
- 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaThe Lancet, 2022
- Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimenInternational Journal of Infectious Diseases, 2019
- Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analysesJournal of Clinical Epidemiology, 2016
- Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant TuberculosisEBioMedicine, 2015
- Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten casesJournal of Infection, 2006